Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open Label, Non-randomized Study of Second or Third Line Treatment With the Combination of Sorafenib and Everolimus in Patients Affected by Relapsed and Non-resectable High-grade Osteosarcoma

NCT01804374 is registered in ClinicalTrials.gov with Italian Sarcoma Group as lead sponsor.

NCT NCT01804374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01804374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open Label, Non-randomized Study of Second or Third Line Treatment With the Combination of Sorafenib and Everolimus in Patients Affected by Relapsed and Non-resectable High-grade Osteosarcoma
Lead sponsor
Italian Sarcoma Group
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2011
Completion date
December 31, 2014
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic osteosarcoma, relapsed osteosarcoma